Events

Adamed aims to become a European champion: Karolina Adamkiewicz discusses expansion in Spain at the Bloomberg Forum

8 May 2026

Karolina Adamkiewicz, MD, PhD, Business Development Director at Adamed Pharma and a representative of the third generation of the company’s owners, took part in the “What’s driving CEE’s M&A deal boom?” panel at the Bloomberg Future of Finance in CEE Forum in Warsaw. 

The discussion focused on the mergers and acquisitions market in Central and Eastern Europe and the growing activity of companies from the region in international markets. 

“I would like to see even more Polish companies investing abroad and evolving from national champions into European champions. This is certainly our ambition as well,” said Karolina Adamkiewicz. 

During the discussion, she spoke about the planned acquisition of the manufacturing plant in Riells, Spain, and the importance of the Spanish market to Adamed’s growth. 

Spain: Adamed’s second-largest market after Poland 

“Spain is our second-largest market after Poland. We have been present there since 2009 and have developed the market organically, step by step. Spain was therefore a natural direction for our growth in Western Europe.” 

Karolina Adamkiewicz explained that in the pharmaceutical industry, building a plant from scratch and transferring production to it is a multi-year process that requires numerous regulatory approvals. 

“Registration processes take years, and the technology transfer of products to an operational plant can take another two years,” she noted. 

Acquiring an operating facility can therefore significantly accelerate Adamed’s development in Europe. 

More than an acquisition: a partnership with Sanofi 

Karolina Adamkiewicz emphasised that the Riells project is not merely the purchase of a factory, but also a long-term partnership. 

“The transaction with Sanofi is unique because it also means entering into a partnership. From the outset, we had to present ourselves not only as an interested buyer but also as a credible manufacturer and partner, because we will continue producing Sanofi medicines in Riells for several years.” 

Generic medicines are increasingly important to Europe 

Karolina Adamkiewicz also highlighted changes in the European pharmaceutical market. Generic medicines are becoming increasingly important to the accessibility of treatment and medicine security. 

Today, seven out of ten medicines dispensed in the European Union are generics, rising to nine out of ten for critical medicines. At the same time, the sector is facing price pressure, rising raw-material and packaging costs and the effects of geopolitical instability. 

Adamed is therefore pursuing international growth and diversification of manufacturing locations to strengthen Europe’s medicine security. 

A Polish family-owned company with no plans to sell 

Karolina Adamkiewicz also underlined that Adamed remains a family-owned company with 100% Polish capital. 

“I represent the third generation of the family that owns Adamed. In our case, succession has already begun. I am actively involved in the company’s operations, and we have no plans to sell the business.” 

The message from the Bloomberg Forum was clear: Adamed intends to grow in Europe, build a stronger manufacturing base and remain a Polish family-owned company.